ReviewMolecular & cellular oncology2026
Evolutionary perspectives on endometrial cancer: antagonistic pleiotropy.
Review in Molecular & cellular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of endometrial cancer is increasing worldwide, with a particularly marked rise in early-onset cases. Modern environmental and lifestyle factors, including low parity, delayed childbirth, obesity, insulin resistance, and chronic inflammation, are thought to contribute to this trend. Although TCGA-based molecular classification has revealed substantial heterogeneity-such as defects in DNA repair, constitutive activation of the PI3K-AKT-mTOR pathway, and disruption of the p53 pathway-the reasons these abnormalities preferentially accumulate in endometrial cancer remain incompletely understood. In this review, we reinterpret the molecular pathogenesis of endometrial cancer through the frameworks of evolutionary mismatch and antagonistic pleiotropy, conceptualizing the disease as a continuum linking reproduction, aging, and tumorigenesis. We integrate evidence from molecular oncology, reproductive biology, and evolutionary medicine to examine how key signaling pathways acquire dual roles across the lifespan. The PI3K-AKT-mTOR pathway is indispensable for reproductive function and endometrial regeneration, yet becomes chronically overactivated under contemporary conditions of overnutrition and obesity, thereby promoting hyperplasia and tumorigenesis. Similarly, the p53 pathway supports genome integrity and placental function during reproduction, but age- and inflammation-associated dysregulation induces cellular senescence and facilitates tumor progression. Importantly, these pathways interact and reinforce each other, amplifying oncogenic phenotypes such as TP53 mutations and PI3K hyperactivation. Collectively, the molecular alterations observed in endometrial cancer can be understood as maladaptive consequences of reproductive systems shaped by evolution but exposed to modern environments. Therefore, an evolutionary medicine perspective may provide a coherent framework for understanding the development of endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.